Jiangxi Fushine Pharmaceutical Co Ltd (300497) - Net Assets
Based on the latest financial reports, Jiangxi Fushine Pharmaceutical Co Ltd (300497) has net assets worth CN¥2.17 Billion CNY (≈ $317.24 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.44 Billion ≈ $649.40 Million USD) and total liabilities (CN¥2.27 Billion ≈ $332.16 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Jiangxi Fushine Pharmaceutical Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.17 Billion |
| % of Total Assets | 48.85% |
| Annual Growth Rate | 24.93% |
| 5-Year Change | -28.57% |
| 10-Year Change | 265.13% |
| Growth Volatility | 37.13 |
Jiangxi Fushine Pharmaceutical Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Jiangxi Fushine Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 300497 total asset value for the complete picture of this company's asset base.
Annual Net Assets for Jiangxi Fushine Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual net assets of Jiangxi Fushine Pharmaceutical Co Ltd from 2011 to 2024. For live valuation and market cap data, see Jiangxi Fushine Pharmaceutical Co Ltd (300497) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.18 Billion ≈ $318.55 Million |
-11.89% |
| 2023-12-31 | CN¥2.47 Billion ≈ $361.55 Million |
-8.14% |
| 2022-12-31 | CN¥2.69 Billion ≈ $393.58 Million |
-7.61% |
| 2021-12-31 | CN¥2.91 Billion ≈ $426.02 Million |
-4.48% |
| 2020-12-31 | CN¥3.05 Billion ≈ $445.98 Million |
+99.52% |
| 2019-12-31 | CN¥1.53 Billion ≈ $223.52 Million |
+33.21% |
| 2018-12-31 | CN¥1.15 Billion ≈ $167.80 Million |
+18.62% |
| 2017-12-31 | CN¥966.71 Million ≈ $141.46 Million |
+23.28% |
| 2016-12-31 | CN¥784.17 Million ≈ $114.75 Million |
+31.53% |
| 2015-12-31 | CN¥596.21 Million ≈ $87.24 Million |
+110.48% |
| 2014-12-31 | CN¥283.26 Million ≈ $41.45 Million |
+23.29% |
| 2013-12-31 | CN¥229.76 Million ≈ $33.62 Million |
+24.46% |
| 2012-12-31 | CN¥184.60 Million ≈ $27.01 Million |
+53.17% |
| 2011-12-31 | CN¥120.52 Million ≈ $17.64 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Jiangxi Fushine Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 174.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥264.52 Million | 12.13% |
| Common Stock | CN¥550.00 Million | 25.22% |
| Other Comprehensive Income | CN¥159.71 Million | 7.32% |
| Other Components | CN¥1.21 Billion | 55.32% |
| Total Equity | CN¥2.18 Billion | 100.00% |
Jiangxi Fushine Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Jiangxi Fushine Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NRW Holdings Limited
F:3NR
|
$1.52 Billion |
|
CBIZ Inc
NYSE:CBZ
|
$1.52 Billion |
|
FLEX LNG Ltd
NYSE:FLNG
|
$1.52 Billion |
|
Beijing VRV Software Corp Ltd
SHE:300352
|
$1.53 Billion |
|
Hefei Jianghang Aircraft Equipment Corporation Ltd
SHG:688586
|
$1.52 Billion |
|
Zhejiang Jiangshan Chemical Co Ltd
SHE:002061
|
$1.52 Billion |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
$1.52 Billion |
|
dentalcorp Holdings Ltd
TO:DNTL
|
$1.52 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jiangxi Fushine Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,484,798,826 to 2,180,472,645, a change of -304,326,181 (-12.2%).
- Net loss of 272,100,550 reduced equity.
- Dividend payments of 55,501,097 reduced retained earnings.
- Share repurchases of 18,000,000 reduced equity.
- Other comprehensive income increased equity by 145,410,425.
- Other factors decreased equity by 104,134,959.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-272.10 Million | -12.48% |
| Dividends Paid | CN¥55.50 Million | -2.55% |
| Share Repurchases | CN¥18.00 Million | -0.83% |
| Other Comprehensive Income | CN¥145.41 Million | +6.67% |
| Other Changes | CN¥-104.13 Million | -4.78% |
| Total Change | CN¥- | -12.25% |
Book Value vs Market Value Analysis
This analysis compares Jiangxi Fushine Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.73x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 47.44x to 4.73x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.41 | CN¥19.32 | x |
| 2012-12-31 | CN¥0.62 | CN¥19.32 | x |
| 2013-12-31 | CN¥0.73 | CN¥19.32 | x |
| 2014-12-31 | CN¥0.91 | CN¥19.32 | x |
| 2015-12-31 | CN¥1.92 | CN¥19.32 | x |
| 2016-12-31 | CN¥1.79 | CN¥19.32 | x |
| 2017-12-31 | CN¥2.23 | CN¥19.32 | x |
| 2018-12-31 | CN¥2.58 | CN¥19.32 | x |
| 2019-12-31 | CN¥3.26 | CN¥19.32 | x |
| 2020-12-31 | CN¥6.50 | CN¥19.32 | x |
| 2021-12-31 | CN¥5.29 | CN¥19.32 | x |
| 2022-12-31 | CN¥4.98 | CN¥19.32 | x |
| 2023-12-31 | CN¥4.58 | CN¥19.32 | x |
| 2024-12-31 | CN¥4.09 | CN¥19.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jiangxi Fushine Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -12.48%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -23.10%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 2.08x
- Recent ROE (-12.48%) is below the historical average (12.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 29.74% | 12.30% | 0.83x | 2.93x | CN¥23.79 Million |
| 2012 | 21.71% | 11.12% | 0.76x | 2.58x | CN¥21.62 Million |
| 2013 | 19.62% | 10.18% | 0.82x | 2.36x | CN¥22.10 Million |
| 2014 | 18.87% | 10.46% | 0.81x | 2.23x | CN¥25.11 Million |
| 2015 | 15.70% | 16.15% | 0.57x | 1.69x | CN¥33.98 Million |
| 2016 | 23.00% | 22.77% | 0.55x | 1.85x | CN¥98.31 Million |
| 2017 | 18.95% | 18.53% | 0.54x | 1.91x | CN¥83.86 Million |
| 2018 | 17.45% | 16.74% | 0.53x | 1.97x | CN¥83.10 Million |
| 2019 | 20.53% | 22.59% | 0.52x | 1.74x | CN¥156.84 Million |
| 2020 | 10.62% | 21.39% | 0.37x | 1.35x | CN¥18.57 Million |
| 2021 | 1.70% | 3.42% | 0.31x | 1.62x | CN¥-239.19 Million |
| 2022 | -5.28% | -8.59% | 0.33x | 1.89x | CN¥-409.60 Million |
| 2023 | -8.08% | -12.47% | 0.33x | 1.94x | CN¥-449.28 Million |
| 2024 | -12.48% | -23.10% | 0.26x | 2.08x | CN¥-490.15 Million |
Industry Comparison
This section compares Jiangxi Fushine Pharmaceutical Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,109,695,154
- Average return on equity (ROE) among peers: 0.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jiangxi Fushine Pharmaceutical Co Ltd (300497) | CN¥2.17 Billion | 29.74% | 1.05x | $1.52 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $108.47 Million | -73.31% | 2.66x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.66 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $-14.51 Million | 0.00% | 0.00x | $443.33 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $660.31 Million | 2.17% | 0.39x | $438.41 Million |
| Chengzhi Shareholding Co Ltd (000990) | $930.16 Million | 5.16% | 0.80x | $2.24 Billion |
| Hualan Biological EngineeringInc (002007) | $3.88 Billion | 15.17% | 0.04x | $3.86 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $269.70 Million | 9.75% | 0.10x | $1.19 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $12.48 Billion | 6.70% | 0.16x | $5.40 Billion |
| Baolingbao Biology Co Ltd (002286) | $703.11 Million | 6.09% | 0.47x | $572.48 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.55 Billion | 15.33% | 0.16x | $1.90 Billion |
About Jiangxi Fushine Pharmaceutical Co Ltd
Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride… Read more